Banking

Lam Research Receives IBD Rating Upgrade, Forms Base

Lam Research (LRCX) saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96.




X



The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.

Lam Research is currently forming a flat base, with a 673.90 entry. Look for the stock to break out in heavy trade at least 40% above average. Keep in mind that it’s a later-stage base, which makes it a riskier entry point.


See How IBD Helps You Make More Money In Stocks


 

Lam Research stock earns a 95 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 95% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

In Q3, the company reported 88% EPS growth. Top line growth climbed 54%, up from 34% in the prior quarter. That marks one quarter of accelerating revenue gains. Lam’s next quarterly report is expected on or around July 29.

Lam Research earns the No. 5 rank among its peers in the Electronics-Semiconductor Equipment industry group. ASML Holdings (ASML) is the No. 1-ranked stock within the group.

YOU MIGHT ALSO LIKE:

Which Companies Are Now Outperforming 95% Of All Stocks?

See Which Stocks Just Came On — And Off — IBD’s Top Stock Lists

Identify Bases And Buy Points With Pattern Recognition From MarketSmith

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button